Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...
Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study Various pharmacologic strategies have been ...
Giving the bolus thrombolytic tenecteplase in a mobile stroke unit resulted in signs of improved efficacy compared with the standard of care thrombolytic alteplase, without any safety concerns, in a ...
The VE response to I.V. bolus infusion of Dox is largely unkown, although Dox is used parenterally in the treatment of apnea of infancy. The objectives of this study were 1) to determine if VE ...
People aged 16 or over at high risk of severe illness or death from sepsis in acute hospital settings have an intravenous fluid bolus within 1 hour of risk being identified, unless contraindicated.
The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results